These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Modulation of the effects of the cannabinoid agonist, ACPA, on spatial and non-spatial novelty detection in mice by dopamine D1 receptor drugs infused into the basolateral amygdala.
    Author: Mohammadi M, Nasehi M, Zarrindast MR.
    Journal: Behav Brain Res; 2015 Mar 01; 280():36-44. PubMed ID: 25476564.
    Abstract:
    AIM: The amygdala is a major target of midbrain dopaminergic neurons and is implicated in learning and memory processes. This study investigates the effect of basolateral amygdale (BLA) dopamine receptors on spatial and non-spatial novelty detection deficit, induced by a selective CB1 cannabinoid receptor agonist (Arachidonylcyclopropylamide; ACPA), during a non-associative task. METHODS: Male mice weighing 30-35 g were used. Open field procedure was employed to assess the spatial and non-spatial memory retention. RESULTS: Our data showed that post-training intraperitoneal injection of ACPA (0.02 mg/kg), intra-BLA microinjection of SKF38393 (D1 dopamine receptor agonist; at higher dose, 0.1 μg/mouse) and SCH23390 (D1 dopamine receptor antagonist; at lowest dose, 0.005 μg/mouse) impaired both spatial and non-spatial novelty detection. Moreover, intra-BLA microinjection of subthreshold dose of SKF38393 or SCH23390 restored and potentiated the spatial and non-spatial novelty detection impairment caused by ACPA, respectively. CONCLUSION: Our results suggested that the ACPA induced impairment of memory retention, may occur through BLA D1 dopamine receptors.
    [Abstract] [Full Text] [Related] [New Search]